- Conditions
- Sarcoidosis, Cardiac
- Interventions
- Namilumab
- Drug
- Lead sponsor
- Kinevant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced May 22, 2026, 4:15 AM EDT